Retrieved on:
Tuesday, February 13, 2024
Software,
Research,
Professional Services,
Data Management,
Technology,
Medical Devices,
Hospitals,
Health Technology,
Security,
Data Analytics,
Clinical Trials,
Science,
Health,
PHD,
Inflation,
Drug development,
GM,
PAS,
Standard of care,
Applied science,
Safety,
Organization,
Patient,
Clinical trial,
Privacy,
IRA,
Ecosystem,
Public sector,
Premier,
Pharmaceutical industry Through this new and expanded effort, PAS will leverage Datavant’s trial tokenization solution and data connectivity platform to link clinical trial data and PAS real-world data and generate real-world evidence that propels clinical research innovation.
Key Points:
- Through this new and expanded effort, PAS will leverage Datavant’s trial tokenization solution and data connectivity platform to link clinical trial data and PAS real-world data and generate real-world evidence that propels clinical research innovation.
- This will provide deeper insights into the benefits and risks of medical interventions in real-world settings within and beyond the controlled environments of clinical trials.
- In another clinical trial, a sponsor is building a real-world evidence control arm using PAS’ real-world data connected by Datavant at the patient level while preserving patient privacy.
- “We’ve now tokenized over 100 clinical trials, and we’re excited to broaden our work with PAS and accelerate innovation with connected data.”
Retrieved on:
Wednesday, January 24, 2024
Patient,
RWD,
Hospital,
Alzheimer's disease,
Health,
Partnership,
PAS,
Language,
Risk,
PHD,
Safety,
Therapy,
Neurodegenerative disease,
Biomarker,
Human,
Parkinson's disease,
Depression,
Medical device NEW YORK, Jan. 24, 2024 /PRNewswire/ -- LANGaware, an innovative leader in digital cognitive and behavioral health diagnostics, is announcing that it will partner with Premier's (NASDAQ: PINC) PINC AI™ Applied Sciences (PAS) to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.
Key Points:
- PAS, renowned for its robust data gleaned from over 4,350 hospitals and 300,000 continuum-of-care providers nationwide, will provide expertise in conducting prospective research utilizing retrospective synthetic arms built from the PINC AI™ Healthcare Database (PHD).
- "Neurodegenerative diseases like Alzheimer's and Parkinson's and behavioral health conditions such as depression affect millions of people worldwide," said Denise Juliano, Group Vice President of Life Sciences at PINC AI™ Applied Sciences.
- The collaboration signifies a significant step forward in expanding access to advanced diagnostic services across the United States.
- By combining PAS' extensive network of health systems and PINC AI's RWD capabilities with LANGaware's cutting-edge technology, the partnership aims to revolutionize healthcare by driving innovation in early detection and treatment.
Retrieved on:
Tuesday, December 12, 2023
Health,
Technology,
Practice Management,
Managed Care,
General Health,
Clinical Trials,
Artificial Intelligence,
AI,
Research,
PAS,
RWD,
TFS,
Data analysis,
Partnership,
RWE,
Pharmaceutical industry Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.
Key Points:
- Premier, Inc.’s PINC AI™ Applied Sciences (PAS) and TFS HealthScience are announcing a landmark collaboration to accelerate global clinical trials and research innovation, improve patient outcomes and reduce health disparities.
- The partnership will combine TFS’ capabilities, systems and clinical development expertise with PAS’ AI-enabled technology and comprehensive healthcare database .
- Eighty percent of all trials face premature termination or significant delays due to recruitment challenges – and marginalized populations, including Black and Hispanic individuals, remain historically underrepresented .
- By uniting their capabilities, PAS and TFS are committed to driving forward innovation in clinical research and offering efficient solutions that prioritize patient health outcomes and equity.
